XML 13 R4.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Operations - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Revenue:    
Net product sales $ 86,270 $ 78,715
Cost of goods sold 6,942 7,582
Gross profit 79,328 71,133
Operating expenses:    
Research and development 41,499 81,517
Selling, general, and administrative 73,957 58,116
Changes in fair value of contingent consideration payable 251 (1,188)
Loss on impairment of assets 0 6,616
Depreciation and amortization 1,257 1,411
Total operating expenses 116,964 146,472
Loss from operations (37,636) (75,339)
Other (expense) income:    
Interest income 2,199 133
Interest expense (11,844) (8,147)
Other (expense) income (5,938) 1,902
Loss before income tax (53,219) (81,451)
Income tax benefit (expense) 287 (3,809)
Net loss attributable to common stockholders $ (52,932) $ (85,260)
Net loss attributable to common stockholders per common share - basic (in dollars per share) $ (0.18) $ (0.30)
Net loss attributable to common stockholders per common share — diluted (in dollars per share) $ (0.18) $ (0.30)
Weighted average common shares outstanding - basic (in shares) 291,336,750 288,481,741
Weighted average common shares outstanding - diluted (in shares) 291,336,750 288,481,741